Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001794:Blood Pressure; D002097:C-Reactive Protein / Q000032:analysis; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D020097:Natriuretic Peptide, Brain; D009419:Nerve Tissue Proteins / Q000097:blood; D010431:Pentoxifylline / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014463:Ultrasonography; D016277:Ventricular Function, Left / Q000187:drug effects; D019014:fas Receptor / Q000097:blood
D000276:Adjuvants, Immunologic; D009419:Nerve Tissue Proteins; D010446:Peptide Fragments; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D002097:C-Reactive Protein; D010431:Pentoxifylline